15
Participants
Start Date
July 31, 2012
Primary Completion Date
January 31, 2014
Study Completion Date
March 31, 2014
ISIS-APOCIIIRX
3 doses of ISIS ISIS-APOCIIIRX on alternate days during the first week and then once-weekly doses for 12 weeks.
Placebo
3 doses of placebo on alternate days during the first week and then once-weekly doses for 12 weeks.
Profil Institute for Clinical Research, Chula Vista
Lead Sponsor
Ionis Pharmaceuticals, Inc.
INDUSTRY